COSM: COSM: C‑Scrub/C‑Sept hit $1.5M annualized in UK/Greece; company targets $7.4M revenue and $5.3M gross profit by 2028

AI Summary

Cosmos Health says its antiseptic brands C‑Scrub and C‑Sept have generated more than $1.5M in combined annualized sales across the UK and Greece and it disclosed a three‑year plan targeting $2.5M revenue in 2026, $4.2M in 2027 and $7.4M in 2028 with gross profit of about $5.3M (implied ~72% margins). The company notes established retail and hospital distribution (UK Amazon listings with ~900 ratings, Tesco, Superdrug, and Greek hospitals), plans broader EU expansion and an extension into animal healthcare, but the targets are forward‑looking and not guaranteed.

Positives

More than $1.5M combined annualized sales for C‑Scrub and C‑Sept across UK and Greece
High reported gross margins (~72%), implying strong profitability on sales
Existing retail and hospital distribution (Amazon with ~900 reviews, Tesco, Superdrug, and Greek hospitals) and planned EU/animal‑health expansion

Negatives

Current sales concentrated in only two markets (UK and Greece); execution required for EU rollout
Three‑year revenue and profit figures are forward‑looking targets and may not be achieved
Growth projections depend on successful entry into additional channels (EU hospitals, animal healthcare) and carry typical market, regulatory and currency risks